Physician profile
Tad C Tillemans
NPI 1346459765
$655,948.52
in general payments reported to CMS, 2019-2025
26 companies · $132K in 2025
The $132K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $58K · 2021: $35K · 2022: $93K · 2023: $116K · 2024: $124K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $254K · Honoraria: $42K · Consulting Fee: $39K · Travel and Lodging: $26K · Food and Beverage: $11K · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $253,805.50 |
| Honoraria | $42,075.00 |
| Consulting Fee | $39,250.00 |
| Travel and Lodging | $25,902.43 |
| Food and Beverage | $11,128.50 |
| Education | $104.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $519,980.07 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $89,487.74 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $29,628.40 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $8,140.61 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $4,757.66 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $997.00 | 2021-2025 | Vraylar |
| Alkermes, INC. | $564.65 | 2020-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $361.54 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $313.37 | 2020-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $304.86 | 2021-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $260.90 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $258.30 | 2020-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $185.96 | 2020-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.21 | 2022 | |
| Braeburn INC. | $118.02 | 2024 | Brixadi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $93.38 | 2022-2024 | Perseris |
| Noven Therapeutics, LLC | $75.36 | 2024 | Secuado, Xelstrym |
| Corium, LLC | $61.43 | 2022-2024 | Azstarys |
| Tris Pharma INC | $57.88 | 2023-2024 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $51.73 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $31.90 | 2019 | |
| Jazz Pharmaceuticals INC. | $31.64 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.96 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.09 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $14.62 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $14.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tad Tillemans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.